Optimal dosing of fluconazole for treatment of candidemia

被引：0
|
作者：
Elizabeth Dodds Ashley
机构：
来源：
Current Fungal Infection Reports | 2009年 / 3卷 / 2期
关键词：
Minimum Inhibitory Concentration; Candidiasis; Antimicrob Agent; Infectious Disease Society; Candida Parapsilosis;
D O I：
10.1007/s12281-009-0009-7
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：63 / 65
页数：2
相关论文
共 50 条
  • [21] Fluconazole Dosing for the Prevention or Treatment of Invasive Candidiasis in Young Infants
    Wade, Kelly C.
    Benjamin, Daniel K., Jr.
    Kaufman, David A.
    Ward, Robert M.
    Smith, Phillip B.
    Jayaraman, Bhuvana
    Adamson, Peter C.
    Gastonguay, Marc R.
    Barrett, Jeffrey S.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2009, 28 (08) : 717 - 723
  • [22] Fluconazole plus amphotericin B combinations are not contraindicated and may add benefit for the treatment of candidemia
    Odds, FC
    CLINICAL INFECTIOUS DISEASES, 2003, 36 (10) : 1229 - 1231
  • [23] HIGH DOSE INTRAVENOUS FLUCONAZOLE IN THE TREATMENT OF CANDIDEMIA IN A CRITICALLY ILL MORBIDLY OBESE PATIENT
    Kalabalik, Julie
    Dhanaliwala, Fatema
    Brunetti, Luigi
    Vigdor, Stuart
    Doherty, Nancy
    Herman, David
    CRITICAL CARE MEDICINE, 2012, 40 (12) : U347 - U347
  • [24] Effectiveness of echinocandins versus fluconazole for treatment of persistent candidemia: A time-dependent analysis
    Lin, Kuan-Yin
    Chen, Pao-Yu
    Chuang, Yu-Chung
    Wang, Jann-Tay
    Sun, Hsin-Yun
    Sheng, Wang-Huei
    Chen, Yee-Chun
    Chang, Shan-Chwen
    JOURNAL OF INFECTION, 2018, 77 (03) : 242 - 248
  • [25] Optimization of Fluconazole Dosing for the Prevention and Treatment of Invasive Candidiasis Based on the Pharmacokinetics of Fluconazole in Critically Ill Patients
    Boonstra, J. M.
    Martson, A. G.
    Sandaradura, I
    Kosterink, J. G. W.
    van der Werf, T. S.
    Marriott, D. J. E.
    Zijlstra, J. G.
    Touw, D. J.
    Alffenaar, J. W. C.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (03)
  • [26] Association of Fluconazole Pharmacodynamics with Mortality in Patients with Candidemia Reply
    Baddley, John W.
    Ostrosky-Zeichner, Luis
    Bhavnani, Sujata M.
    Andes, David R.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (06) : 2705 - 2706
  • [27] A Risk Score for Fluconazole Failure among Patients with Candidemia
    Ostrosky-Zeichner, Luis
    Harrington, Rachel
    Azie, Nkechi
    Yang, Hongbo
    Li, Nanxin
    Zhao, Jing
    Koo, Valerie
    Wu, Eric Q.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (05)
  • [28] Treatment of tuberculosis and optimal dosing schedules
    Chang, Kwok Chiu
    Leung, Chi Chiu
    Grosset, Jacques
    Yew, Wing Wai
    THORAX, 2011, 66 (11) : 997 - 1007
  • [29] Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia
    Gebremedhin Beedemariam Gebretekle
    Atalay Mulu Fentie
    Girma Tekle Gebremariam
    Eskinder Eshetu Ali
    Daniel Asfaw Erku
    Tinsae Alemayehu
    Workeabeba Abebe
    Beate Sander
    BMC Health Services Research, 22
  • [30] A RANDOMIZED TRIAL COMPARING FLUCONAZOLE WITH AMPHOTERICIN-B FOR THE TREATMENT OF CANDIDEMIA IN PATIENTS WITHOUT NEUTROPENIA
    REX, JH
    BENNETT, JE
    SUGAR, AM
    PAPPAS, PG
    VANDERHORST, CM
    EDWARDS, JE
    WASHBURN, RG
    SCHELD, WM
    KARCHMER, AW
    DINE, AP
    LEVENSTEIN, MJ
    WEBB, CD
    NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (20): : 1325 - 1330
12345